Radioactive drug for previously treated gut or adrenal tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new radioactive drug, [212Pb]VMT-alpha-NET, that targets a receptor found on some tumor cells. It is for people with certain gut or adrenal gland tumors that have already been treated with a similar therapy but are still growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of cancer called gastrointestinal neuroendocrine tumor (GI NET) or pheochromocytoma/paraganglioma (PPGL) that has spread or cannot be removed by surgery.
- You have already had at least one treatment with a targeted radiation therapy that goes through your bloodstream.
- A recent PET scan shows that more than half of your tumor has a specific receptor (SSTR) that the study drug targets.
- Your disease has been getting worse (growing or more symptoms) in the last 3 years.
- You are 18 years or older, and your overall health is good enough to be up and about (ECOG score 0 or 1).
- Your kidney, liver, and blood cell counts are within safe levels as checked by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new radioactive drug (called [212Pb]VMT-Alpha-NET) that targets a marker on certain cancer cells. It may help shrink or slow the growth of tumors that have spread or can't be removed, and it's being studied for several cancer types, including neuroendocrine tumors, small cell lung cancer, kidney cancer, and some head and neck cancers.
This trial tests a targeted form of radiation made to stick to specific “somatostatin receptor” markers on tumors. It is designed for people with advanced, receptor-positive neuroendocrine tumors or meningioma who may have had prior treatments and need more options.
This trial tests a type of radiation therapy called Lu-177 Dotatoc (PRRT) for people with neuroendocrine tumors or other cancers that have high levels of a specific protein (sst2). It may be an option when standard treatments stop working or aren't available.
This trial tests a radioactive drug called [177Lu]Lu-DOTA-TATE for people with advanced neuroendocrine tumors (GEP-NET) that have grown or spread. The drug targets tumor cells that have a specific receptor (SSTR) and delivers radiation directly to them, aiming to slow or shrink the tumors while limiting damage to healthy tissue.
This trial tests a radioactive treatment (Lutathera) for people with certain neuroendocrine tumors (NETs) that are not in the stomach or intestines)Skip to content
This trial tests a new type of PET scan using a radioactive tracer called 61Cu-NODAGA-LM3 to detect neuroendocrine tumors (NETs). The goal is to see if it works as well as or better than the standard scan. If you have a NET and need a scan for staging or treatment planning, you might be able to join.
Hear when a new Somatostatin Receptor Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.